Exelixis: Positive Pancreatic Cancer Data Brings Two Big Catalysts On Deck (NASDAQ:EXEL)

Female tech checks readout during experiments in lab

SDI Productions/E+ via Getty Images

Exelixis (NASDAQ:EXEL) has made great progress in advancing its drug known as CABOMETYX for the treatment of several types of cancer. It has already been able to receive approval of this drug for

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *